United Therapeutics (UTHR) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
16 Nov, 2026Commercial performance and TYVASO momentum
Q3 total revenue was $833M; TYVASO franchise revenue reached a record $504M.
TYVASO growth reflected strong referrals and starts, effective messaging, and deeper physician engagement; the expanded sales force is expected to contribute more in Q4 and 2027.
October referrals across the commercial portfolio exceeded 1,000, a record for one month, indicating continued momentum.
PH-ILD remains under-penetrated and a major growth driver; PAH is also growing, though more modestly.
Settlement guardrails and the expanded sales force are expected to support TYVASO uptake among new PH-ILD patients over time; payer coverage changes may vary.
IPF and PPF opportunities
FDA accepted the sNDA for nebulized TYVASO in IPF; the stated PDUFA date is April 26, and preparations include nebulizers and starter kits for at least 10,000 patients.
TETON-1 and TETON-2 results were characterized as highly positive; management expects substantial, rapid uptake, while noting real-world discontinuation may differ from trial experience.
TETON PPF trial results are expected to be unblinded in Q3 and Q4 2027.
Pipeline and regulatory milestones
Ralinepag NDA for PAH was accepted, with a PDUFA date at the end of June 2027; management expects a once-daily oral prostacyclin to have significant opportunity in PAH.
SMI filing timing shifted from end-2026 to 2027 after an FDA meeting identified additional CMC and PK work; no patient-outcome data are expected to be needed.
Sinopharm is working with the FDA to address inspection findings; the existing ralinepag timeline remains possible, while alternative manufacturers are being evaluated as a contingency.
Latest events from United Therapeutics
- Record commercial performance sets up a busy 2027 of FDA decisions and pipeline milestones.UTHR
Jefferies Global Healthcare Conference - Record revenue and product growth offset lower earnings and pipeline execution risks.UTHR
Q3 2026 - Expanding into pulmonary fibrosis with strong clinical data and major revenue growth targets.UTHR
Morgan Stanley 24th Annual Global Healthcare Conference - Disruptive therapies and organ manufacturing drive exponential growth and innovation.UTHR
Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - Pulmonary fibrosis breakthroughs and 14 launches drive a projected 10x revenue surge.UTHR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Aggressive product launches and innovation aim for $50–100B revenue and industry leadership.UTHR
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenues fell 2% to $783.3M, but net income rose 8% to $333M on Tyvaso DPI growth.UTHR
Q2 2026 - Record growth, breakthrough pulmonary fibrosis results, and pioneering xenotransplantation trials.UTHR
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum - Q2 2024 revenue up 20% to $715M, net income $278.1M, Tyvaso led growth, $1B buyback completed.UTHR
Q2 2024